relapsed/refractory acute myeloid leukemia

Trials

45 participants · First posted Feb 12, 2020

Unknown

NCT05731219

UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

18 participants · First posted Feb 16, 2023

Recruiting

NCT06763341

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

12 participants · First posted Jan 8, 2025

Drugs

View all 557 →

Small Molecule

Approved

Gilteritinib(Xospata)

Conditions: Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

C₂₉H₄₄N₈O₃ · Rx

Acute Myeloid Leukemia(Advesya)

Small Molecule

Approved

Enasidenib(Idhifa)

Conditions: Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)

C₁₉H₁₇F₆N₇O

Organizations

View all 52 →

Nkarta

United States

Cardiff Oncology

United States

MYELOID THERAPEUTICS

United States

News

View all 6103 →

last year

FDA Grants Fast Track Designation to HC-7366 for Relapsed/Refractory AML

last year

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia

last year

Trials

CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia

UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Drugs

Gilteritinib(Xospata)

Acute Myeloid Leukemia(Advesya)

Enasidenib(Idhifa)

Organizations

Nkarta

Cardiff Oncology

MYELOID THERAPEUTICS

News

FDA Grants Fast Track Designation to HC-7366 for Relapsed/Refractory AML

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia

FDA Approves Expanded Pediatric Trial for Moleculin's Annamycin in Acute Myeloid Leukemia